Sentences with phrase «drugs imatinib»
The drug imatinib mesylate (Gleevec) is shown to be effective against chronic myelogenous leukemia (CML).
http://cancerresearch.org/ Not exact matches
The analysis suggests that patients with complex indels in KIT would benefit from drugs such as imatinib, sunitnib and sorafenib, which target mutations in this gene.
The team tested a combination of PGE1 and the TKI drug called imatinib in a mouse model of CML.
Medical treatment usually involves either imatinib mesylate (Gleevec ®) sunitinib (Sutent ®), or investigational drugs through clinical trials.
After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML, which led to FDA approval of the drug in record time.
Several targeted drugs (e.g., imatinib [Gleevec ®], dasatinib [Sprycel ®]-RRB- are effective for treating CML because they attack cells with the Philadelphia chromosome, the genetic abnormality that is the hallmark of this type of leukemia.
It has been shown in imatinib - resistant CML that drug resistance conferred by mutations does not necessarily correlate with proliferative advantage and increased kinase activity.34 Other, non-activating mutations or drug - resistance mechanisms, might be acquired by tumor cells.
Novartis unbelievably went as far as paying specialty pharmacies to recommend Tasigna to Medicare and Medicaid patients who were trying to fill prescriptions for other drugs (potentially generic imatinib) and to downplay the side effects of Tasigna to patients considering switching drugs.
He has played a key role in the discovery and development of multiple approved drugs, including imatinib (Gleevec), dasatinib (Sprycel), and enzalutamide (Xtandi).
In a significant, yet unusual judgment the Court of Justice of the European Union (CJEU) upheld the General Court's decision (T - 140 / 12; Teva Pharma v. EMA) that had affirmed the European Medicines Agency's (EMA) rejection of Teva's generic drug application for Glivec ® (active substance - imatinib), not due to the reference product's own orphan drug exclusivity but in view of orphan drug exclusivity of a similar medicinal product — Tasigna ® (active substance - nilotinib).
However, the General Court upheld the EMA's decision refusing Teva's generic application for imatinib in view of nilotinib's orphan drug exclusivity pertaining to CML.